Acute Myeloid LeukemiaPhase 1NCT06626633
2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML
A Phase 1 study testing CRD3874 in people with Acute Myeloid Leukemia, run by University of Maryland, Baltimore at 1 site in United States.
Trial summary
This clinical research study is being done to answer questions about how to treat cancer. To clear cancer cells from the body, the immune system needs the action of proteins called Type 1 interferons. The protein STING (for STimulator of INterferon Genes) stimulates the body to make Type 1 interferons. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Myeloid Leukemia
- What is being tested?
- CRD3874
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 6 participants
- Where
- 1 siteUnited States
- Study dates
- 26 Aug 2024to 31 Jan 2028
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female age ≥ 18 years at the time of signing the ICF
- Able to understand and willing to provide written informed consent
- Willing to comply with clinical study instructions and requirements.
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 (Appendix 1).
- Pathologically confirmed diagnosis of AML by 2022 International Consensus Classification of Myeloid Neoplasms and Acute Leukemias criteria (2)
- AML may be de novo, following a prior hematologic disorder including myelodysplastic syndrome or Philadelphia chromosome-negative myeloproliferative neoplasm, and/or therapy-related
Show all 20Show fewer
- Patients must have relapsed/refractory AML, with any prior therapies and any number of prior therapies, and have no further standard therapies available.
- Any prior therapy must have been completed ≥2 weeks prior to Day 1 of treatment on study, and all treatment-related adverse events (except alopecia) should have recovered to <Grade 1.
- Hematologic abnormalities that are thought to be primarily related to leukemia are not considered to be toxicities and do not need to resolve to <Grade 1.
- Myeloid growth factors must have been stopped ≥1 week (filgrastim) or ≥2 weeks (pegfilgrastim) before starting study treatment.
- Prior autologous hematopoietic stem cell transplantation is allowed.
- Prior allogeneic hematopoietic stem cell transplantation is also allowed, if patients are ≥60 days from stem cell infusion, have no evidence of graft-versus-host disease (GVHD) >Grade 1, and are >4 weeks off calcineurin therapy and ≥2 weeks off all immunosuppressive therapy.
- Peripheral blast count must be <50 × 109/L. Hydroxyurea is permitted for blast count control before starting study treatment, but must be stopped ≥24 hours before starting study treatment. It may be reintroduced per physician decision if >50 × 109/L blasts recur during treatment Cycle 1 and managed per physician decision.
- Patients with other malignancies are allowed, if other malignancies are inactive and not requiring concurrent therapy except hormonal therapy for stable breast or prostate cancer.
- Aspartate aminotransferase (AST) must be <2.5 x Upper Limit Normal (ULN), alanine aminotransferase (ALT) <2.5 x ULN and total serum bilirubin <1.5 x ULN unless thought due to hemolysis or Gilbert's Syndrome.
- Adequate renal function as defined by calculated creatinine clearance (CrCl) >60 ml/minute by the Cockcroft-Gault formula
- Left ventricular ejection fraction (LVEF) >50%, as measured by echocardiogram (2D-ECHO)
- Life expectancy of at least three months at screening, according to the Investigator's opinion
- Women of childbearing potential (defined as a sexually mature female who has not undergone a hysterectomy or bilateral oophorectomy or who has not been naturally postmenopausal for at least 24 consecutive months) must have a negative serum or urine pregnancy test within 7 days of study entry.
- Women of childbearing potential and sexually active men with female partners of childbearing potential must agree to use effective contraception, including abstinence or two forms of contraception, during study treatment and for four weeks after the last dose odf study drug.
Who cannot join
- Acute promyelocytic leukemia
- Blast phase of chronic myeloid leukemia
- Known active central nervous system leukemia
- Concurrent chemotherapy, radiation therapy, immunotherapy or other investigational agents
- Active, uncontrolled infection
- Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements in the investigator's judgment
Show all 38Show fewer
- Malignancies other than AML requiring active therapy except hormonal therapy for stable breast or prostate cancer
- Active autoimmune disease other than vitiligo, type 1 diabetes, or controlled hypothyroidism
- Interstitial lung disease or any disease requiring supplemental oxygen, or history of pneumonitis or pulmonary fibrosis from any cause
- Known prior severe hypersensitivity to an investigational product or any component of the study drug therapy's formulations including polyethylene glycol (PEG; National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v5.0 Grade ≥ 3)
- Prior chemotherapy or targeted small molecule therapy within 3 weeks, anticancer monoclonal antibody within four weeks or five half-lives, if shorter, or radiation therapy within 2 weeks prior to the first CRD3874-SI infusion prior to study Day 1, or not recovered (i.e., Grade ≤ 1 or at baseline) from AE due to a previously administered agent (Note: Alopecia is acceptable. If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study therapy)
- Prior organ transplantation, other than allogeneic or autologous hematopoietic stem cell transplantation.
- Currently participating in a study and receiving study therapy, or participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment or 5 half-lives, whichever is longer.
- Received a live vaccine within 30 days of the planned start of study drug. (Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines and are not allowed.)
- Evidence of clinically significant immunosuppression including the following:
- Primary immunodeficiency state such as SCID
- Concurrent opportunistic infection
- Receiving systemic immunosuppressive therapy (>2 weeks) including oral steroid doses > 10 mg/day of prednisone or equivalent within seven days prior to enrollment. In the setting of non-immune mediated indications for use, chronic/active low dose steroid use (equivalent to ≤ 10 mg/day prednisone) may be permitted at the discretion of the Principal Investigator (Note: Other steroid formulations or steroid use for other indications may be permitted and include: 1) Intranasal, inhaled, ocular, or topical steroids, or local steroid injection (e.g., intra-articular injection); 2) Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent; 3) Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
- History or evidence of symptomatic autoimmune disease (e.g., pneumonitis, glomerulonephritis, vasculitis, or other), or history of active autoimmune disease that has required systemic treatment (i.e., use of corticosteroids, immunosuppressive drugs or biological agents used for treatment of autoimmune diseases) in past two years prior to enrollment (Note: Replacement therapy [e.g., thyroxine for hypothyroidism, insulin for diabetes or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency] is not considered a form of systemic treatment for autoimmune disease.)
- Evidence of clinically significant interstitial lung disease, history of interstitial lung disease, or active, noninfectious pneumonitis related to prior immunotherapy treatment
- Uncontrolled medical condition including current active infection requiring systemic therapy or symptomatic congestive heart failure (CHF) within six months that in the Investigator's opinion compromises the ability of the participant to complete all study-related requirements safely
- Mean resting corrected QTcF interval ≥ 470 ms on a 12-lead electrocardiogram (ECG) for males and females
- History of unstable or deteriorating cardiovascular disease within the previous six months prior to screening, including but not limited to the following:
- Unstable angina or myocardial infarction (MI)
- Cerebrovascular accident (CVA)/stroke
- CHF (New York Heart Association [NYHA] Class III or IV)
- Uncontrolled clinically significant arrhythmias
- Known to be positive for active Hepatitis B (HBV; Hepatitis B surface antigen [HBsAg] reactive with detectable HBV DNA), or Hepatitis C (HCV; detectable HCV RNA [qualitative])
- Patients with chronic HBV (positive HBsAg and/or Hepatitis B core antibody [HBcAb] and negative HBV DNA by polymerase chain reaction [PCR]) are eligible for this study if they are on suppressive antiviral therapy and deemed safe by a gastroenterologist
- Patients who are HCV antibody (Ab)-positive but HCV RNA-negative due to prior treatment or natural resolution will be considered eligible
- Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies) disease that is not controlled. Individuals known to be HIV-positive will be considered eligible if all the following criteria are met:
- Established antiretroviral treatment (ART) for at least four weeks and have an HIV viral load less than 400 copies/mL prior to enrollment
- CD4+ T-cell counts ≥ 350 cells/uL
- No opportunistic infection within the past 12 months
- No known history of active tuberculosis (TB)
- The presence of a concurrent active malignancy that in the opinion of the Investigator could compromise the conduct of the study or interfere with determining the outcomes of the study objectives
- Women who are pregnant or breastfeeding
- Expecting to conceive or father children within the projected duration of the study, starting with the prescreening or screening visit through three months after the last dose of study treatment(s)
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Maryland, Baltimore
Baltimore, Maryland, 21201
About this study
Official title: Phase 1 Clinical Trial of the STING Agonist CRD3874-SI in Patients With Relapsed/Refractory Acute Myeloid Leukemia
This clinical research study is being done to answer questions about how to treat cancer.
To clear cancer cells from the body, the immune system needs the action of proteins called Type 1 interferons. The protein STING (for STimulator of INterferon Genes) stimulates the body to make Type 1 interferons. Type 1 interferons activate key molecules in cancer immunity to kill cancer cells.
CRD3874 is a synthetic drug that activates STING, and STING stimulates the immune system to kill cancer cells. In experiments on blood from humans, CRD3874 makes blood cells produce molecules responsible for anti-cancer activity. CRD3874 was tested in mice with cancers including leukemia, head and neck cancer, lung cancer, pancreatic cancer and sarcoma. In these mice, CRD3874 made tumors shrink or disappear, and some mice developed long-lasting immunity against cancer. Also, when CRD3874 was given with other anti-cancer treatments, it increased their anti-cancer effects.
- Conditions
- Acute Myeloid Leukemia
- Being tested
- CRD3874
- Medical subject headings
- Leukemia, Myeloid, Acute
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CRD3874Drug
CRD3874-SI is a STING agonist. CRD3874 is a synthetic drug that activates STING, and STING stimulates the immune system to kill cancer cells. In experiments on blood from humans, CRD3874 makes blood cells produce molecules responsible for anti-cancer activity. CRD3874 was tested in mice with cancers including leukemia, head and neck cancer, lung cancer, pancreatic cancer and sarcoma. In these mice, CRD3874 made tumors shrink or disappear, and some mice developed long-lasting immunity against cancer.
| Study group | Role | What they receive |
|---|---|---|
| STING agonist CRD3874-SI in patients with relapsed/refractory acute myeloid leukemia | Experimental | Drug Product: CRD3874 solution for injection (CRD3874-SI) Type of drug: Synthetic small molecule Formulation: Sterile solution of CRD3874 for injection Route of Administration: IV infusion over one hour Strength: 6 mg/mL Schedule: Cycle: once weekly infusion x 4 (Days 1, 8, 15 and 22) over 28-day for Cycles 1 and 2. For Cycle 3 and onward, weekly infusion x 3 (Days 1, 8 and 15), until they develop unacceptable toxicities or disease progression, or do not achieve at least a morphologic leukemia-free state response after 6 cycles. Receives: Drug: CRD3874 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety and Tolerability by multiplex cytokine profiling
To evaluate the safety and tolerability of CRD3874-SI (a STING agonist) in patients with relapsed/refractory acute myeloid leukemia and to determine the biologically effective dose and recommended Phase 2 dose (RP2D).
Exploratory studies will include measurement of additional cytokines including IFNα, IL-1α, IL-1β, IL-10, IFN-γ, TNFα, MCP-1 and GM-CSF by multiplex cytokine profiling
Measured: 2 years
Safety and Tolerability by qPCR
To evaluate the safety and tolerability of CRD3874-SI (a STING agonist) in patients with relapsed/refractory acute myeloid leukemia and to determine the biologically effective dose and recommended Phase 2 dose (RP2D).
STING and immediate downstream targets (IRF3, IRF7, TBK1, STAT6) and NFKB pathway (GADD45a, TNFx, JUNB, NFKB2, IL7R, IKK) and IFN pathway (IFNB, ISG15, ISG20, IFI27, IFI44) targets by qPCR,
Measured: 2 years
Safety and Tolerability by Western blot analysis
To evaluate the safety and tolerability of CRD3874-SI (a STING agonist) in patients with relapsed/refractory acute myeloid leukemia and to determine the biologically effective dose and recommended Phase 2 dose (RP2D).
STING and downstream targets including TBK1, IRF3 and IRF7, STAT6 and TNFx and phosphorylated/activated counterparts by Western blot analysis
Measured: 2 years
Safety and Tolerability by colony formation assays
To evaluate the safety and tolerability of CRD3874-SI (a STING agonist) in patients with relapsed/refractory acute myeloid leukemia and to determine the biologically effective dose and recommended Phase 2 dose (RP2D).
Bcl-2 family proteins by Western blot analysis, apoptosis by flow cytometry and clonogenic potential by colony formation assays.
Measured: 2 years
Secondary outcomes (4)
Area under the plasma concentration versus time curve (AUC)
PK parameters will include area under the curve (AUC) in ng·hr/mL
Measured: 2 years
Peak Plasma Concentration (Cmax)
PK parameters will include maximum concentration (Cmax) in ng/mL
Measured: 2 years
Trough Concentration (Ctrough)
PK parameters will include trough concentration (Ctrough) in ng/mL. Blood samples will be collected. Plasma will be used for PK studies.
Measured: 2 years
Pharmacodynamic (PD) effects of CRD3874-SI
PD endpoint will be measurement of STING pathway-relevant cytokines CXCL10, IL6 and IFNβ levels in plasma.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Oct 2024
- Study start26 Aug 2024
- Primary completion25 Aug 2025
- Study completion31 Jan 2028 (estimated)
Why it stopped: Pharmaceutical Company withdrew support and investigational product
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Myeloid LeukemiaStudies of the same condition, open and under way.
- More trials run by University of Maryland, BaltimoreThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- STING agonist CRD3874-SI in patients with relapsed/refractory acute myeloid leukemia
- Masking
- None (open label)
- Enrolment
- 6 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Maryland, Baltimore
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06626633
- Sponsor's protocol ID
- 2321GCCC ; HP-00105008
- Status last verified
- Mar 2026
- First submitted
- 1 Aug 2024
- Last updated
- 12 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase 1 Clinical Trial of the STING Agonist CRD3874-SI in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- ClinicalTrials.gov ID
- NCT06626633
- Acronym / sponsor ID
- 2321GCCC ; HP-00105008
- Conditions
- Acute Myeloid Leukemia
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- SuspendedReason stopped: Pharmaceutical Company withdrew support and investigational product
- Enrolment
- 6 participants (actual)
- Lead sponsor
- University of Maryland, BaltimoreUniversity, hospital or other
- Study start
- 26 Aug 2024 (actual)
- Primary completion
- 25 Aug 2025 (actual)
- Study completion
- 31 Jan 2028 (estimated)
- First posted
- 4 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical research study is being done to answer questions about how to treat cancer.
To clear cancer cells from the body, the immune system needs the action of proteins called Type 1 interferons. The protein STING (for STimulator of INterferon Genes) stimulates the body to make Type 1 interferons. Type 1 interferons activate key molecules in cancer immunity to kill cancer cells.
CRD3874 is a synthetic drug that activates STING, and STING stimulates the immune system to kill cancer cells. In experiments on blood from humans, CRD3874 makes blood cells produce molecules responsible for anti-cancer activity. CRD3874 was tested in mice with cancers including leukemia, head and neck cancer, lung cancer, pancreatic cancer and sarcoma. In these mice, CRD3874 made tumors shrink or disappear, and some mice developed long-lasting immunity against cancer. Also, when CRD3874 was given with other anti-cancer treatments, it increased their anti-cancer effects.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- STING agonist CRD3874-SI in patients with relapsed/refractory acute myeloid leukemia
| Arm | Type | Receives |
|---|---|---|
| STING agonist CRD3874-SI in patients with relapsed/refractory acute myeloid leukemia | Experimental | Drug: CRD3874Drug Product: CRD3874 solution for injection (CRD3874-SI) Type of drug: Synthetic small molecule Formulation: Sterile solution of CRD3874 for injection Route of Administration: IV infusion over one hour Strength: 6 mg/mL Schedule: Cycle: once weekly infusion x 4 (Days 1, 8, 15 and 22) over 28-day for Cycles 1 and 2. For Cycle 3 and onward, weekly infusion x 3 (Days 1, 8 and 15), until they develop unacceptable toxicities or disease progression, or do not achieve at least a morphologic leukemia-free state response after 6 cycles. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (20 listed)
- Male or female age ≥ 18 years at the time of signing the ICF
- Able to understand and willing to provide written informed consent
- Willing to comply with clinical study instructions and requirements.
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 (Appendix 1).
- Pathologically confirmed diagnosis of AML by 2022 International Consensus Classification of Myeloid Neoplasms and Acute Leukemias criteria (2)
Key exclusion criteria (38 listed)
- Acute promyelocytic leukemia
- Blast phase of chronic myeloid leukemia
- Known active central nervous system leukemia
- Concurrent chemotherapy, radiation therapy, immunotherapy or other investigational agents
- Active, uncontrolled infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CRD3874CRD3874-SI is a STING agonist. CRD3874 is a synthetic drug that activates STING, and STING stimulates the immune system to kill cancer cells. In experiments on blood from humans, CRD3874 makes blood cells produce molecules responsible for anti-cancer activity. CRD3874 was tested in mice with cancers including leukemia, head and neck cancer, lung cancer, pancreatic cancer and sarcoma. In these mice, CRD3874 made tumors shrink or disappear, and some mice developed long-lasting immunity against cancer. | Drug | STING agonist CRD3874-SI in patients with relapsed/refractory acute myeloid leukemia |
Primary outcome
Safety and Tolerability by multiplex cytokine profiling
Time frame: 2 years
To evaluate the safety and tolerability of CRD3874-SI (a STING agonist) in patients with relapsed/refractory acute myeloid leukemia and to determine the biologically effective dose and recommended Phase 2 dose (RP2D). Exploratory studies will include measurement of additional cytokines including IFNα, IL-1α, IL-1β, IL-10, IFN-γ, TNFα, MCP-1 and GM-CSF by multiplex cytokine profiling
Safety and Tolerability by qPCR
Time frame: 2 years
To evaluate the safety and tolerability of CRD3874-SI (a STING agonist) in patients with relapsed/refractory acute myeloid leukemia and to determine the biologically effective dose and recommended Phase 2 dose (RP2D). STING and immediate downstream targets (IRF3, IRF7, TBK1, STAT6) and NFKB pathway (GADD45a, TNFx, JUNB, NFKB2, IL7R, IKK) and IFN pathway (IFNB, ISG15, ISG20, IFI27, IFI44) targets by qPCR,
Safety and Tolerability by Western blot analysis
Time frame: 2 years
To evaluate the safety and tolerability of CRD3874-SI (a STING agonist) in patients with relapsed/refractory acute myeloid leukemia and to determine the biologically effective dose and recommended Phase 2 dose (RP2D). STING and downstream targets including TBK1, IRF3 and IRF7, STAT6 and TNFx and phosphorylated/activated counterparts by Western blot analysis
Safety and Tolerability by colony formation assays
Time frame: 2 years
To evaluate the safety and tolerability of CRD3874-SI (a STING agonist) in patients with relapsed/refractory acute myeloid leukemia and to determine the biologically effective dose and recommended Phase 2 dose (RP2D). Bcl-2 family proteins by Western blot analysis, apoptosis by flow cytometry and clonogenic potential by colony formation assays.
4 secondary outcomes
Area under the plasma concentration versus time curve (AUC)
Time frame: 2 years
Peak Plasma Concentration (Cmax)
Time frame: 2 years
Trough Concentration (Ctrough)
Time frame: 2 years
Pharmacodynamic (PD) effects of CRD3874-SI
Time frame: 2 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Mar 2026.
Related trials for Acute Myeloid Leukemia
RecruitingPhase 1
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
AML (Acute Myeloid Leukemia)
RecruitingPhase 2
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Active, not recruitingPhase 2
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
RecruitingPhase 1/2
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia
Not yet recruitingPhase 1
ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS
Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing CRD3874 in people with Acute Myeloid Leukemia, run by University of Maryland, Baltimore at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 20 inclusion and 38 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: paused, as of the sponsor's last update on 12 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety and Tolerability by multiplex cytokine profiling (time frame: 2 years). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2026.